fall within the scope of the claims of the invention.

What is claimed is:

1. A polypeptide comprising:

(I) the structure as shown in Formula I,

X1-X2-X3(A5)-X4-X5(A1)-X6(A2)-X7-X8-X9(A3)-X10-X11(A4)-X12-X13-X14-X15-X16

Formula I, or

(II) a sequence having one or more amino acid substitutions, deletions, additions and/or replacements in the structure as shown in Formula I, or


(III) a sequence having 90% or more similarity to the structure as shown in Formula I, or

a pharmaceutically acceptable salt, solvate, chelate or non-covalent complex formed from the polypeptide comprising the structure as shown in Formula I; or

a prodrug based on the polypeptide comprising the structure as shown in Formula I; or

a mixture comprising a pharmaceutically acceptable salt, solvate, chelate or non-covalent complex formed from the polypeptide comprising the structure as shown in Formula I and/or a prodrug based on the polypeptide comprising the structure as shown in Formula I;

wherein:

X1 is selected from Suc, Fum, MeO-Fum, Ac, SA, MA, FA, A1-D or A1-NH-C_2H_4-NH-Suc, X2 is selected from D, E or K(A1), or X1 and X2 as a whole are ;

X3 is selected from E, D or K(A1);

X4 is selected from E, E(C16) or D;

X5 is selected from A, K, R, H, E or D;

X6 is selected from V, I, K, Dab, Orn, L, F, W or C;

X7 is selected from Y, F or W;

X8 is selected from F, Y or W;

X9 is selected from A, K, R, H, D, E, Dab or Orn;


X10 is selected from H, K or R;

X11 is selected from K, L, L(N-Me), I, V, Cit, H, R, L-2-amino-4-guanidinobutyric acid or Orn;

X12 is selected from D or E;

X13 is selected from I, I(N-Me), 2-Abu, L, P or V;

X14 is selected from I, 2-Abu, L or V;

X15 is selected from W, F, Y or 


;

X16 is selected from OH or NH_2;

A5 is C or absent;

A1, A2, A3 or A4 independently comprises Y1-Y2-Y3-Y4;


Y1 is -NH-$(CH_2$-CH_2-O$)_{m1}$-$(CH_2)_{m2}$-CO-, L/D-Glu, -CPAK- or absent, wherein L/D-Glu is attached to the amino group on the side chain of an amino acid on the backbone of the polypeptide through an α- or γ-carboxyl group, and to a carboxyl group of Y2 through the amino group;

Y2 is -NH-$(CH_2$-CH_2-O$)_{m3}$-$(CH_2)_{m4}$-CO-, 

MPA or absent;

Y3 is -NH-$(CH_2$-CH_2-O$)_{m5}$-$(CH_2)_{m6}$-CO-, L/D-Glu, or absent, wherein L/D-Glu is attached to an amino group of Y2 through an α- or γ-carboxyl group, and to a carboxyl group of Y4 through an amino group;

Y4 is D-Biotin, a group having the structure as shown in Formula 2, HOOC-$(CH_2)_n$-CO, CH_3-$(CH_2)_n$-CO or absent,



Formula 2;

m1, m2, m3, m4, m5 or m6 is an integer from 1 to 10;


n is an integer selected from 10 to 25;

only one of A1, A2, A3, and A4 is present, or all of A1, A2, A3, and A4 are absent; and

the polypeptide having the structure of Formula I does not include Suc-DEEAVYFAHLDIIW.

2. The polypeptide of claim 1, wherein:

X1 is selected from Suc, Fum, MeO-Fum, Ac, SA, MA, FA, (ODDA-γE-AEEA-AEEA-)D or (ODDA-γE-AEEA-AEEA-)NH-C_2H_4-NH-Suc,

X2 is D or K(A1), or X1 and X2 as a whole are ;

X3 is E or K(A1);

X4 is selected from E or E(C16);

X5 is selected from A, K or E;

X6 is selected from V, K, Dab, L, F or C;

X7 is Y;

X8 is F;

X9 is selected from A, K or E;


X10 is H;

X11 is selected from K, L, L(N-Me), R, Cit, L-2-amino-4-guanidinobutyric acid or Orn;

X12 is D;

X13 is selected from I, I(N-Me), 2-Abu, P or V;

X14 is I;

X15 is selected from W or 

;

A1 is -γE-AEEA-AEEA-ODDA, ODDA-γE-AEEA-AEEA-, Biotin, -AEEA-AEEA-γE-ODDA or absent;

A2 is -γE-AEEA-AEEA-ODDA or absent;

A3 is -γE-AEEA-AEEA-ODDA or absent;

A4 is -AEEA-AEEA-γE-ODDA, -γE-AEEA-AEEA-C18, -γE-AEEA-AEEA-C16, -γE-AEEA-AEEA-C12, -γE-AEEA-AEEA-B, -γE-AEEA-AEEA-ODDA, CPAK-MPA-, -AEEA-γE-C18, -AEEA-γE-C16, -AEEA-γE-C12, -AEEA-E-C12 or absent.

3. The polypeptide of claim 1 or 2, wherein the polypeptide comprising the structure shown in Formula I is a cyclic peptide formed by:

(I) a disulfide bond between two Cs in the structure; and/or

(II) an amide bond between a carboxyl group at the side chain of a D or an E and an amino group at the side chain of a K or a Dab.

4. The polypeptide of claim 3, wherein the cyclic peptide is formed by:


(I) a disulfide bond between A5 which is a C and X6 which is a C; and/or




(II) an amide bond between X3 which is an E and X6 which is a K or Dab; and/or


(III) an amide bond between X5 which is an E and X11 which is a K.

5. The polypeptide of claim 1, wherein the polypeptide has sequence as forth in any one of SEQ ID NO: 2-88 as follows:

SEQ ID No.	Sequence
2	Suc-DEEAVYFAHKDIIW
3	Fum-DEEAVYFAHKDIIW
4	Suc-DEEAVYFAHLDVIW
5	Suc-DEEAVYFAHLD(2-Abu)IW
6	Fum-DEEAVYFAHK(-AEEA-AEEA-γE-ODDA)DIIW
7	Suc-DEEAKYFAHLDIIW
8	Suc-DEEEVYFAHKDIIW
9	Suc-D cyclo(EEAK)YFAHLDIIW
10	Suc-D cyclo(EEADab)YFAHLDIIW
11	Suc-DEE cyclo(EVYFAHK)DIIW
12	Fum-DEEAVYFAHOrn(-AEEA-AEEA-γE-ODDA)DIIW
13	Fum-DEEEVYFAHKDIIW
14	Suc-DEEEVYFAHOrnDIIW
15	Suc-DEEEVYFAHK(-AEEA-AEEA-γE-ODDA)DIIW
16	Suc-DE cyclo(CEEC)YFAHKDIIW
17	MeO-Fum-DEEEVYFAHKDIIW
18	Fum-DEEEVYFAHOrnDIIW
19	Fum-DEEEVYFAHK(-AEEA-AEEA-γE-ODDA)DIIW
20	Suc-DEEAVYFAHOrn(-AEEA-AEEA-γE-ODDA)DIIW
21	Fum-DEE cyclo(EVYFK)HKD(2-Abu)IW
22	Suc-D cyclo(EEAK)YFAHLD(2-Abu)IW
23	Fum-D cyclo(EEAK)YFAHLD(2-Abu)IW
24	MeO-Fum-D cyclo(EEAK)YFAHLD(2-Abu)IW
25	Fum-DEEK(-γE-AEEA-AEEA-ODDA)VYFAHLDIIW
26	Fum-DEEAK(-γE-AEEA-AEEA-ODDA)YFAHLDIIW
27	Fum-DEEAVYFK(-γE-AEEA-AEEA-ODDA)HLDIIW
28	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-C18)DIIW
29	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-C16)DIIW
30	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-C12)DIIW

31	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-B)DIIW
32	Suc-DEEAVYFAHK(-γE-AEEA-AEEA-ODDA)DIIW
33	MeO-Fum-DEEAVYFAHK(-γE-AEEA-AEEA-ODDA)DIIW
34	Suc-D cyclo(EEAK)YFAHLDVIW
35	Suc-D cyclo(EEAK)YFAHK(-γE-AEEA-AEEA-ODDA)DIIW
36	Suc-DEEAVYFAHK(-γE-AEEA-AEEA-ODDA)DVIW
37	Suc-D cyclo(EEAK)YFAHK(-γE-AEEA-AEEA-ODDA)DVIW
38	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-ODDA)DIIW-NH2
39	Fum-DEEAVYFAHK(CPAK-MPA-)DIIW  MPA
40	Fum-D cyclo(EEAK)YFAHLDVIW
41	Fum-D cyclo(EEAK)YFAHK(-γE-AEEA-AEEA-ODDA)DVIW
42	Fum-DEEAVYFAHK(-γE-AEEA-AEEA-ODDA)DVIW
43	Fum-D cyclo(EEAK)YFAHLDIIW
44	Fum-D cyclo(EEAK)YFAHK(-γE-AEEA-AEEA-ODDA)DIIW
45	Fum-D cyclo(EEAK)YFAHK(-γE-AEEA-AEEA-ODDA)D(2-Abu)IW
46	Fum-DEEAKYFAHLDIIW
47	Fum-DEEAKYFAHLDVIW
48	Fum-DEEAKYFAHK(-γE-AEEA-AEEA-ODDA)DIIW
49	Fum-DEEAKYFAHK(-γE-AEEA-AEEA-ODDA)DVIW
50	Fum-DEEAK(-γE-AEEA-AEEA-ODDA)YFAHLDIIW
51	Fum-DEEAK(-γE-AEEA-AEEA-ODDA)YFAHLDVIW
52	SA-DEEAVYFAHLDIIW
53	MA-DEEAVYFAHLDIIW

54	Fum-DEEAVYFAHKDIIW1 W1: 
55	suc-DEEAVYFAHR1DIIW (R1=L-2-amino-4-guanidinobutyric acid)
56	Fum-DEEAVYFAHOrnDIIW
57	Fum-DEEAVYFAHCitDIIW
58	Suc-DE cyclo(CEAC)YFAHLDIIW
59	Fum-DEEAVYFAHKDVIW
60	Fum-DEEAVYFAHKD(2-Abu)IW
61	Suc-DEEAVYFAHLDI(N-Me)IW
62	Suc-DEEAVYFAHL(N-Me)DIIW
63	Suc-DEEAVYFAHL(N-Me)DI(N-Me)IW
64	Fum-DEEAVYFAHL(N-Me)DIIW
65	Fum-DEEAVYFAHL(N-Me)DI(N-Me)IW
66	Fum-DEEAVYFAHLDVIW
67	Fum-DEEAVYFAHLD(2-Abu)IW
68	 QP1
69	
70	FA-DEEAVYFAHKDIIW
71	Fum-DEEE(Biotin)VYFAHKDIIW
72	suc-DEEAVYFAHLDPIW
73	Fum-DEE(C16)AVYFAHLDIIW
74	Suc-DEEAVYFAHRDIIW
75	Fum-DEEALYFAHKDIIW
76	Fum-DEEAFYFAHKDIIW
77	Fum-DEEAVYFAHK(-AEEA-γE-C18)DIIW

78	Fum-DEEAVYFAHK(-AEEA-γE-C16)DIIW
79	Fum-DEEAVYFAHK(-AEEA-γE-C12)DIIW
80	Fum-K(-AEEA-AEEA-γE-ODDA)EEAVYFAHLDIIW
81	Fum-DK(-AEEA-AEEA-γE-ODDA)EAVYFAHLDIIW
82	(ODDA-γE-AEEA-AEEA-)DDEEAVYFAHLDIIW
83	(ODDA-γE-AEEA-AEEA-)NH-C2H4-NH-Suc-DEEAVYFAHLDIIW
84	 EEAVYFAHK(ODDA-γE-AEEA-AEEA-)DIIW
86	Fum-DEEAVYFAHK(-AEEA-γE-C12)DVIW
87	Fum-DEEAVYFAHK(-AEEA-E-C12)DVIW
88	Suc-DE cyclo(CEEC)YFAHLDIIW

.

6. A method of preparing the polypeptide of any one of claims 1 to 5, comprising the following steps:

Step 1: obtaining a peptide resin of the polypeptide via solid-phase polypeptide synthesis; and

Step 2: cleaving and purifying to obtain the polypeptide.

7. A polypeptide prepared according to the method of claim 6.

8. A medicament comprising the polypeptide of any one of claims 1-5 and 7 and a pharmaceutically acceptable excipient or adjuvant.

9. A pharmaceutical composition comprising the medicament of claim 8 and an additional active ingredient.

10. A polypeptide of any one of claims 1-5 and 7, a medicament of claim 8, or a pharmaceutical composition of claim 9, for use in therapy.

11. A polypeptide of any one of claims 1-5 and 7, a medicament of claim 8, or a pharmaceutical composition of claim 9, in the manufacture of a medicament for the treatment of an ETBR receptor-related disease.

12. The use of claim 11, wherein the ETBR receptor-related disease is one or more selected from the group consisting of stroke, Alzheimer's disease, spinal cord injury, aortic stenosis, and neonatal hypoxic-ischemic encephalopathy.

13. The use of claim 12, wherein the stroke is ischemic stroke and/or hemorrhagic stroke.